OBJECTIVES: Resistance to azole antifungal drugs in Aspergillus fumigatus is now a major clinical problem in some locations. Here we update our previous experience with data from 2008-09. METHODS: We tested all A. fumigatus isolates submitted to the Mycology Reference Centre Manchester in 2008 and 2009 for susceptibility to itraconazole, voriconazole and posaconazole. We undertook CYP51A sequencing for most of the azole-resistant isolates. RESULTS: Of 230 isolates, 64 (28%) were azole resistant. In 2008 and 2009, 14% and 20% of patients had resistant isolates, respectively. During this period 62 of 64 (97%) were itraconazole resistant, 2 of 64 (3%) were only voriconazole resistant and 78% of cases were multi-azole resistant. Forty-three percent of isolates did not carry a cyp51A mutation (previously the most common azole resistance mechanism), indicating that other mechanisms must be responsible and are increasing in frequency. CONCLUSIONS: Azole resistance is evolving and growing in frequency. Established and novel mechanisms may be responsible.
OBJECTIVES: Resistance to azole antifungal drugs in Aspergillus fumigatus is now a major clinical problem in some locations. Here we update our previous experience with data from 2008-09. METHODS: We tested all A. fumigatus isolates submitted to the Mycology Reference Centre Manchester in 2008 and 2009 for susceptibility to itraconazole, voriconazole and posaconazole. We undertook CYP51A sequencing for most of the azole-resistant isolates. RESULTS: Of 230 isolates, 64 (28%) were azole resistant. In 2008 and 2009, 14% and 20% of patients had resistant isolates, respectively. During this period 62 of 64 (97%) were itraconazole resistant, 2 of 64 (3%) were only voriconazole resistant and 78% of cases were multi-azole resistant. Forty-three percent of isolates did not carry a cyp51A mutation (previously the most common azole resistance mechanism), indicating that other mechanisms must be responsible and are increasing in frequency. CONCLUSIONS:Azole resistance is evolving and growing in frequency. Established and novel mechanisms may be responsible.
Authors: Paul Bowyer; Caroline B Moore; Riina Rautemaa; David W Denning; Malcolm D Richardson Journal: Curr Infect Dis Rep Date: 2011-12 Impact factor: 3.725
Authors: Darel Macdonald; Darren D Thomson; Anna Johns; Adriana Contreras Valenzuela; Jane M Gilsenan; Kathryn M Lord; Paul Bowyer; David W Denning; Nick D Read; Michael J Bromley Journal: Antimicrob Agents Chemother Date: 2018-12-21 Impact factor: 5.191
Authors: Simone M T Camps; Jan W M van der Linden; Yi Li; Ed J Kuijper; Jaap T van Dissel; Paul E Verweij; Willem J G Melchers Journal: Antimicrob Agents Chemother Date: 2011-10-17 Impact factor: 5.191
Authors: Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira Journal: Antimicrob Agents Chemother Date: 2012-12-10 Impact factor: 5.191